New vaccine aims to train immune system against hepatitis b

NCT ID NCT06989788

Ongoing ⭐️ VACCINE ⭐️ Sponsor: AstriVax Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new vaccine called AVX70371, designed to treat chronic hepatitis B by training the immune system to fight the virus. It involves 16 healthy adults aged 18 to 40 to check for safety and immune responses. The study is not yet testing if it works against the disease, only if it is safe and triggers an immune reaction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AVX70371 (therapeutic hepatitis B vaccine)
What this could lead to: If successful, this could lead to a treatment that helps the immune system fight chronic hepatitis B, potentially reducing the need for lifelong medication.
What could go wrong: This is a very early Phase 1 trial with only 16 healthy participants, so it is primarily testing safety, not effectiveness. The vaccine may not produce a strong enough immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)

Ghent, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.